Difference between revisions of "Large granular lymphocytic leukemia"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
m |
||
| Line 3: | Line 3: | ||
[[#top|Back to Top]] | [[#top|Back to Top]] | ||
</div> | </div> | ||
| − | { | + | {{#lst:Section editor transclusions|tcl}} |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |} | ||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
| Line 16: | Line 10: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| − | |||
=Guidelines= | =Guidelines= | ||
=="How I Treat"== | =="How I Treat"== | ||
| Line 22: | Line 15: | ||
==[https://www.nccn.org/ NCCN]== | ==[https://www.nccn.org/ NCCN]== | ||
*[https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf NCCN Guidelines - T-cell Lymphomas] - contains information about T-cell Large Granular Lymphocytic Leukemia | *[https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf NCCN Guidelines - T-cell Lymphomas] - contains information about T-cell Large Granular Lymphocytic Leukemia | ||
| − | |||
=Initial therapy= | =Initial therapy= | ||
| − | |||
==Cyclophosphamide monotherapy {{#subobject:464f08|Regimen=1}}== | ==Cyclophosphamide monotherapy {{#subobject:464f08|Regimen=1}}== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
| − | |||
===Regimen {{#subobject:78c71b|Variant=1}}=== | ===Regimen {{#subobject:78c71b|Variant=1}}=== | ||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
| Line 37: | Line 27: | ||
|- | |- | ||
|} | |} | ||
| − | ''These are retrospective series, of which Bareau et al. 2010 is representative. The most common dose reported is 100 mg PO once per day; some authors mentions co-administration of steroids but details are not supplied.'' | + | ''Note: These are retrospective series, of which Bareau et al. 2010 is representative. The most common dose reported is 100 mg PO once per day; some authors mentions co-administration of steroids but details are not supplied.'' |
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Immunosuppressive therapy==== | ====Immunosuppressive therapy==== | ||
*[[Cyclophosphamide (Cytoxan)]] 50 to 100 mg PO once per day | *[[Cyclophosphamide (Cytoxan)]] 50 to 100 mg PO once per day | ||
| − | |||
'''Lamy et al. 2011 recommends that patients who are responding are continued on treatment for 6 to 12 months; patients who do not respond within 4 months of therapy are discontinued''' | '''Lamy et al. 2011 recommends that patients who are responding are continued on treatment for 6 to 12 months; patients who do not respond within 4 months of therapy are discontinued''' | ||
| − | + | </div></div> | |
===References=== | ===References=== | ||
# '''Retrospective:''' Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood. 2001 Jul 15;98(2):483-5. [http://www.bloodjournal.org/content/98/2/483.long link to original article] [https://pubmed.ncbi.nlm.nih.gov?term=11435321 PubMed] | # '''Retrospective:''' Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood. 2001 Jul 15;98(2):483-5. [http://www.bloodjournal.org/content/98/2/483.long link to original article] [https://pubmed.ncbi.nlm.nih.gov?term=11435321 PubMed] | ||
# '''Retrospective:''' Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O, Schleinitz N, Tournilhac O, Roussel M, Fest T, Lamy T. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica. 2010 Sep;95(9):1534-41. [http://www.haematologica.org/content/95/9/1534.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2930955/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20378561 PubMed] content property of [http://hemonc.org HemOnc.org] | # '''Retrospective:''' Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O, Schleinitz N, Tournilhac O, Roussel M, Fest T, Lamy T. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica. 2010 Sep;95(9):1534-41. [http://www.haematologica.org/content/95/9/1534.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2930955/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20378561 PubMed] content property of [http://hemonc.org HemOnc.org] | ||
# '''Retrospective:''' Moignet A, Hasanali Z, Zambello R, Pavan L, Bareau B, Tournilhac O, Roussel M, Fest T, Awwad A, Baab K, Semenzato G, Houot R, Loughran TP Jr, Lamy T. Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia. 2014 May;28(5):1134-6. Epub 2013 Nov 27. [https://doi.org/10.1038/leu.2013.359 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017255/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24280867 PubMed] | # '''Retrospective:''' Moignet A, Hasanali Z, Zambello R, Pavan L, Bareau B, Tournilhac O, Roussel M, Fest T, Awwad A, Baab K, Semenzato G, Houot R, Loughran TP Jr, Lamy T. Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia. 2014 May;28(5):1134-6. Epub 2013 Nov 27. [https://doi.org/10.1038/leu.2013.359 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017255/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24280867 PubMed] | ||
| − | |||
==Methotrexate & Prednisone {{#subobject:9c0e17|Regimen=1}}== | ==Methotrexate & Prednisone {{#subobject:9c0e17|Regimen=1}}== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
| − | |||
===Regimen {{#subobject:3bbb5|Variant=1}}=== | ===Regimen {{#subobject:3bbb5|Variant=1}}=== | ||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
| Line 60: | Line 48: | ||
|- | |- | ||
|} | |} | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Immunosuppressive therapy==== | ====Immunosuppressive therapy==== | ||
*[[Methotrexate (MTX)]] 10 mg/m<sup>2</sup>/day PO in divided doses once per day on days 1, 8, 15, 22 | *[[Methotrexate (MTX)]] 10 mg/m<sup>2</sup>/day PO in divided doses once per day on days 1, 8, 15, 22 | ||
**Details not described in ECOG E5998; Lamy et al. 2011 divides the 10 mg/m<sup>2</sup> methotrexate dose into 5 mg/m<sup>2</sup> in the morning and 5 mg/m<sup>2</sup> in the evening | **Details not described in ECOG E5998; Lamy et al. 2011 divides the 10 mg/m<sup>2</sup> methotrexate dose into 5 mg/m<sup>2</sup> in the morning and 5 mg/m<sup>2</sup> in the evening | ||
*[[Prednisone (Sterapred)]] 1 mg/kg PO once per day for 30 days, then tapered off over 24 days (details not described) | *[[Prednisone (Sterapred)]] 1 mg/kg PO once per day for 30 days, then tapered off over 24 days (details not described) | ||
| − | |||
'''28-day cycles''' | '''28-day cycles''' | ||
| − | + | </div> | |
| + | <div class="toccolours" style="background-color:#cbd5e7"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
*Patients with PR: continue up to one year | *Patients with PR: continue up to one year | ||
*Patients with CR: continue for one month past documented CR | *Patients with CR: continue for one month past documented CR | ||
*Non-responders were transitioned to [[#Cyclophosphamide_.26_Prednisone|cyclophosphamide & prednisone]] | *Non-responders were transitioned to [[#Cyclophosphamide_.26_Prednisone|cyclophosphamide & prednisone]] | ||
| − | + | </div></div> | |
===References=== | ===References=== | ||
# '''ECOG E5998:''' Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, Hasanali Z, Bennett JM, Lazarus HM, Litzow MR, Evens AM, Mustjoki S, Tallman MS. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015 Apr;29(4):886-94. Epub 2014 Sep 13. [https://doi.org/10.1038/leu.2014.298 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377298/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25306898 PubMed] | # '''ECOG E5998:''' Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, Hasanali Z, Bennett JM, Lazarus HM, Litzow MR, Evens AM, Mustjoki S, Tallman MS. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015 Apr;29(4):886-94. Epub 2014 Sep 13. [https://doi.org/10.1038/leu.2014.298 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377298/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25306898 PubMed] | ||
| − | |||
=Relapsed or refractory= | =Relapsed or refractory= | ||
| − | |||
==Cyclophosphamide & Prednisone {{#subobject:3cfd6b|Regimen=1}}== | ==Cyclophosphamide & Prednisone {{#subobject:3cfd6b|Regimen=1}}== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:c27546|Variant=1}}=== | ===Regimen {{#subobject:c27546|Variant=1}}=== | ||
{| class="wikitable" style="width: 60%; text-align:center;" | {| class="wikitable" style="width: 60%; text-align:center;" | ||
| Line 91: | Line 78: | ||
|} | |} | ||
''Note: Patients with PR continue up to one year; patients with CR continue for one month past documented CR.'' | ''Note: Patients with PR continue up to one year; patients with CR continue for one month past documented CR.'' | ||
| + | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
*[[#Methotrexate_.26_Prednisone|Methotrexate & prednisone]], with treatment failure | *[[#Methotrexate_.26_Prednisone|Methotrexate & prednisone]], with treatment failure | ||
| + | </div> | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Immunosuppressive therapy==== | ====Immunosuppressive therapy==== | ||
*[[Cyclophosphamide (Cytoxan)]] 100 mg PO once per day | *[[Cyclophosphamide (Cytoxan)]] 100 mg PO once per day | ||
*[[Prednisone (Sterapred)]] 1 mg/kg PO once per day for 30 days, then tapered off over 24 days (details not described) | *[[Prednisone (Sterapred)]] 1 mg/kg PO once per day for 30 days, then tapered off over 24 days (details not described) | ||
| − | |||
'''28-day cycles (see note)''' | '''28-day cycles (see note)''' | ||
| − | + | </div></div> | |
===References=== | ===References=== | ||
# '''ECOG E5998:''' Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, Hasanali Z, Bennett JM, Lazarus HM, Litzow MR, Evens AM, Mustjoki S, Tallman MS. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015 Apr;29(4):886-94. Epub 2014 Sep 13. [https://doi.org/10.1038/leu.2014.298 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377298/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25306898 PubMed] | # '''ECOG E5998:''' Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, Hasanali Z, Bennett JM, Lazarus HM, Litzow MR, Evens AM, Mustjoki S, Tallman MS. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015 Apr;29(4):886-94. Epub 2014 Sep 13. [https://doi.org/10.1038/leu.2014.298 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377298/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25306898 PubMed] | ||
| − | |||
[[Category:Large granular lymphocytic leukemia regimens]] | [[Category:Large granular lymphocytic leukemia regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:T-cell lymphomas]] | [[Category:T-cell lymphomas]] | ||
Revision as of 12:42, 29 October 2022
3 regimens on this page
3 variants on this page
|
Guidelines
"How I Treat"
- 2011: Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood. 2011 Mar 10;117(10):2764-74. link to original article link to PMC article PubMed
NCCN
- NCCN Guidelines - T-cell Lymphomas - contains information about T-cell Large Granular Lymphocytic Leukemia
Initial therapy
Cyclophosphamide monotherapy
Regimen
| Study | Evidence |
|---|---|
| Bareau et al. 2010 | Retrospective |
Note: These are retrospective series, of which Bareau et al. 2010 is representative. The most common dose reported is 100 mg PO once per day; some authors mentions co-administration of steroids but details are not supplied.
Immunosuppressive therapy
- Cyclophosphamide (Cytoxan) 50 to 100 mg PO once per day
Lamy et al. 2011 recommends that patients who are responding are continued on treatment for 6 to 12 months; patients who do not respond within 4 months of therapy are discontinued
References
- Retrospective: Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood. 2001 Jul 15;98(2):483-5. link to original article PubMed
- Retrospective: Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O, Schleinitz N, Tournilhac O, Roussel M, Fest T, Lamy T. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica. 2010 Sep;95(9):1534-41. link to original article link to PMC article PubMed content property of HemOnc.org
- Retrospective: Moignet A, Hasanali Z, Zambello R, Pavan L, Bareau B, Tournilhac O, Roussel M, Fest T, Awwad A, Baab K, Semenzato G, Houot R, Loughran TP Jr, Lamy T. Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia. 2014 May;28(5):1134-6. Epub 2013 Nov 27. link to original article link to PMC article PubMed
Methotrexate & Prednisone
Regimen
| Study | Evidence |
|---|---|
| Loughran et al. 2014 (ECOG E5998) | Phase 2 |
Immunosuppressive therapy
- Methotrexate (MTX) 10 mg/m2/day PO in divided doses once per day on days 1, 8, 15, 22
- Details not described in ECOG E5998; Lamy et al. 2011 divides the 10 mg/m2 methotrexate dose into 5 mg/m2 in the morning and 5 mg/m2 in the evening
- Prednisone (Sterapred) 1 mg/kg PO once per day for 30 days, then tapered off over 24 days (details not described)
28-day cycles
Subsequent treatment
- Patients with PR: continue up to one year
- Patients with CR: continue for one month past documented CR
- Non-responders were transitioned to cyclophosphamide & prednisone
References
- ECOG E5998: Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, Hasanali Z, Bennett JM, Lazarus HM, Litzow MR, Evens AM, Mustjoki S, Tallman MS. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015 Apr;29(4):886-94. Epub 2014 Sep 13. link to original article contains dosing details in manuscript link to PMC article PubMed
Relapsed or refractory
Cyclophosphamide & Prednisone
Regimen
| Study | Evidence | Efficacy |
|---|---|---|
| Loughran et al. 2014 (ECOG E5998) | Phase 2 | ORR: 64% (95% CI, 35-87) |
Note: Patients with PR continue up to one year; patients with CR continue for one month past documented CR.
Preceding treatment
- Methotrexate & prednisone, with treatment failure
Immunosuppressive therapy
- Cyclophosphamide (Cytoxan) 100 mg PO once per day
- Prednisone (Sterapred) 1 mg/kg PO once per day for 30 days, then tapered off over 24 days (details not described)
28-day cycles (see note)
References
- ECOG E5998: Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, Hasanali Z, Bennett JM, Lazarus HM, Litzow MR, Evens AM, Mustjoki S, Tallman MS. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015 Apr;29(4):886-94. Epub 2014 Sep 13. link to original article contains dosing details in manuscript link to PMC article PubMed